查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999322

生物製藥CMO/CRO市場：2026-2032年全球市場預測（按產品類型、服務類型、治療領域、應用和最終用戶分類）

Biopharmaceutical CMO & CRO Market by Product Type, Service Type, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物製藥 CMO/CRO 市場價值將達到 1,137.4 億美元，到 2026 年將成長至 1,352.5 億美元，到 2032 年將達到 3,865.8 億美元，複合年成長率為 19.09%。

主要市場統計數據
基準年 2025 1137.4億美元
預計年份：2026年 1352.5億美元
預測年份 2032 3865.8億美元
複合年成長率 (%) 19.09%

清晰而有力地概述了日益複雜的治療方案、監管要求和供應韌性如何重新定義全球 CMO 和 CRO 的策略重點。

隨著治療方案的複雜性、監管力度和商業化時間表的不斷變化，策略重點也在不斷重塑，契約製造（CMO）和合約研究（CRO）產業正經歷著快速轉型。外包不再只是降低成本的交易，它已成為加速創新、擴大產能以及在藥物發現、開發和商業化的各個階段分擔風險的核心要素。生物製藥、基因和細胞療法以及模組化生產方法的日益複雜化，推動了對能夠支持從分析測試到臨床供應以及商業填充和包裝等一體化工作流程的合作夥伴的需求。

識別技術、監管和商業性因素的融合，這些融合將從根本上改變 CMO 和 CRO 行業的服務交付模式和競爭優勢。

契約製造和研發產業的格局正受到多項變革的重塑，這些變革並行發展，相互影響。首先，由於治療方法的創新，技術複雜性日益增加。細胞療法、基因療法和先進生物製藥的興起需要新的製程技術、專業設施和訓練有素的人員。因此，對生產能力的投資不僅要擴大規模，還要在嚴格的品質和安全標準下，加快迭代開發週期。

檢驗了近期關稅政策和貿易趨勢的變化如何加劇供應鏈風險，並迫使整個藥品開發和製造外包流程進行策略重組。

影響關稅和貿易流動的政策變化正對全球製造業和臨床供應鏈產生重大影響，預計2025年生效或建議實施的關稅措施的累積效應正在加速整個行業的戰略重新評估。藥品活性成分、一次性組件和專用設備的進口關稅增加，推高了外包生產的總成本，並可能由於採購和海關程序的變化而略微延長前置作業時間。為此，許多申辦者和供應商正在重新評估其供應商所在地，以平衡成本、前置作業時間確定性和監管合規性。

全面的細分洞察，將服務模式、產品複雜性、治療應用和最終用戶特徵與策略能力要求和夥伴關係模式相匹配。

詳細的細分分析揭示了服務類型、產品類型、治療應用和最終用戶群體中，能力、監管要求和商業性優先事項的交匯點。提供的服務包括分析工作流程、細胞培養操作、臨床開發支援、填充和包裝能力、製劑專業知識、臨床前開發和製程開發。臨床開發支持從I期到III期的各項活動，每個階段都有其獨特的監管要點和供應要求。產品類型分為大分子和小分子。大分子包括生物製藥和生物相似藥，其中生物製藥涵蓋單株抗體、重組蛋白和疫苗。小分子涵蓋學名藥和新化學實體（NCE），它們在進入臨床試驗的速度和製造地規模方面各有不同。

對美洲、歐洲、中東和非洲以及亞太生態系統中的設施投資、監管合規和合作夥伴選擇具有區域戰略意義。

地理環境在整個合約研發生產（CDMO）生態系統中，對產能投資、監管策略和商業部署都起著決定性作用。美洲地區擁有成熟的環境，其特點是法規結構完善、生物製藥和先進治療領域人才濟濟，以及大量私人和公共資本流入產能擴張領域，尤其是在物流和臨床生態系統健全的地區。這種環境有利於能夠利用涵蓋研發、臨床試驗執行和商業供應的整合網路的申辦者和供應商。

深入洞察技術深度、策略夥伴關係和數位化驅動的卓越營運如何重新定義醫藥研發和製造外包領域的領導地位。

服務供應商之間的競爭格局日益取決於其技術平台的深度、跨開發階段的整合能力以及應對複雜治療方法的敏捷性。主要企業透過投資專業設施、專有分析平台和自動化技術來降低變異性並加快出貨前測試，從而實現差異化。同時，一些靈活的細節領域服務提供者正利用其特定專長，例如病毒載體生產、CAR-T細胞療法或mRNA產品的先進填充和包裝，提供靈活且以客戶為中心的合約模式，吸引新興生物技術贊助商。

為高階主管提供可操作且優先考慮的建議，以增強整體外包開發和製造流程的營運韌性、監管合應對力和策略夥伴關係。

產業領導者應採取務實且優先的措施，以確保專案進度按計畫進行、提高柔軟性並保障商業性競爭力。首先，申辦方和供應商需要加快對平台技術和模組化設施設計的投資，從而在不影響品質的前提下實現快速分子轉移和可擴展生產。這包括對高影響力功能進行有針對性的資本投資，例如專用病毒載體設施、封閉式細胞療法生產系統以及用於處理溫度敏感製劑的先進填充和包裝生產線。

我們採用嚴謹、透明、多方面的研究途徑，結合高階主管的訪談、技術諮詢和第二手資料，為實務工作者提供見解和建議。

本研究採用多方面方法，旨在確保獲得穩健且可重複的洞見，從而反映當前的行業趨勢和從業者經驗。該調查方法結合了對贊助商、供應商和機構相關人員相關方的高級管理人員進行的定性訪談，以及與工藝科學家、監管專家和供應鏈專家進行的技術諮詢，以檢驗營運影響。這些對話的目的並非得出量化預測，而是為了了解關於產能限制、技術應用和夥伴關係模式的實際觀點。

簡明結論總結了對能力、監管合規和穩固夥伴關係的投資如何決定醫藥研發外包的長期競爭力。

整體情況，產業正處於轉折點，科學創新、日益複雜的營運以及地緣政治趨勢相互交織，重新定義了外包策略。那些有選擇地投資於專業能力、數位化基礎設施和彈性供應鏈網路的贊助商和供應商，將更有能力降低研發專案的風險，並加快患者獲得治療的速度。同樣重要的是，要採用能夠協調獎勵並共同承擔品質和進度責任的夥伴關係架構。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥CMO/CRO市場：依產品類型分類

  • 聚合物化合物
    • 生物製藥
      • 單株抗體
      • 重組蛋白
      • 疫苗
    • 生物相似藥
  • 低分子
    • 學名藥
    • 新化學物質

第9章：生物製藥CMO/CRO市場：依服務類型分類

  • 分析
  • 細胞培養
  • 臨床開發
    • 第一階段
    • 第二階段
    • 第三階段
  • 灌裝/包裝
  • 配方
  • 臨床前開發
  • 製程開發

第10章：生物製藥CMO/CRO市場：依治療領域分類

  • 腫瘤學
  • 感染疾病
  • 循環系統
  • 中樞神經系統
  • 免疫學和炎症
  • 呼吸系統
  • 代謝/內分泌
  • 罕見疾病

第11章：生物製藥CMO/CRO市場：依應用領域分類

  • 細胞療法
    • CAR T
    • 幹細胞
  • 基因治療
    • 非病毒
    • 病毒載體
  • 單株抗體
    • 雙重特異性
    • 組合型
    • 不合格的
  • 重組蛋白
    • 酵素
    • 生長因子
    • 荷爾蒙
  • 疫苗
    • 失活
    • 活病毒疫苗
    • mRNA
    • 次單元

第12章：生物製藥CMO/CRO市場：依最終用戶分類

  • 生技公司
    • 大型生技公司
    • 中小型生技公司
  • CRO
    • 全方位服務
    • 小眾服務
  • 製藥公司
    • 一級
    • 二級
    • 三級
  • 研究機構
    • 學術機構
    • 政府

第13章：生物製藥CMO/CRO市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物製藥CMO/CRO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥CMO/CRO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製藥CMO/CRO市場

第17章：中國生物製藥CMO/CRO市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AbbVie, Inc.
  • arexel International Corporation
  • Baxter International Inc.
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific Limited
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • ICON Plc
  • KBI Biopharma, Inc.
  • KEMWELL BIOPHARMA PRIVATE LIMITED
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Patheon Inc.
  • Rentschler Biopharma SE
  • Sterling Pharma Solutions
Product Code: MRR-3A2E844FDA5E

The Biopharmaceutical CMO & CRO Market was valued at USD 113.74 billion in 2025 and is projected to grow to USD 135.25 billion in 2026, with a CAGR of 19.09%, reaching USD 386.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 113.74 billion
Estimated Year [2026] USD 135.25 billion
Forecast Year [2032] USD 386.58 billion
CAGR (%) 19.09%

A clear and compelling introduction to how therapeutic complexity, regulatory expectations, and supply resilience are redefining CMO and CRO strategic priorities worldwide

The contract manufacturing and contract research landscape is undergoing rapid evolution as therapeutic complexity, regulatory scrutiny, and commercial timelines converge to reshape strategic priorities. Outsourcing is no longer a transactional cost-saving exercise but a core enabler of innovation velocity, capacity scaling, and risk sharing across discovery, development, and commercialization. Increasingly sophisticated biologics, gene and cell therapies, and modular manufacturing approaches are driving demand for partners who can support integrated workflows from analytical testing through clinical supply and commercial fill-finish.

In addition, the industry is contending with amplified expectations around quality, traceability, and regulatory readiness. Sponsors and service providers must coordinate earlier and more closely to align development pathways, technology transfer, and validation strategies, thereby reducing time-to-patient while protecting product integrity. Simultaneously, heightened attention to environmental, social, and governance factors and to supply chain resilience is influencing procurement criteria and capital allocation decisions.

Consequently, successful organizations are investing in platform technologies, cross-functional governance, and strategic collaborations that enable flexible scale-up, accelerated clinical timelines, and predictable commercialization handoffs. This report begins by situating these forces and then explores specific structural shifts that will determine competitive advantage across service lines and geographies.

Identifying the converging technological, regulatory, and commercial forces that will fundamentally transform service delivery models and competitive advantage in the CMO and CRO sector

The landscape for contract manufacturing and research is being reshaped by several transformative shifts that operate in parallel and feed one another. First, therapeutic innovation is increasing technical complexity: the rise of cellular, gene, and advanced biologic modalities requires new process know-how, specialized facilities, and highly trained personnel. As a result, capacity investments are not simply about scale but about the ability to operate within tight quality and safety envelopes while accelerating iterative development cycles.

Second, technology adoption is changing operational models. Digitalization, advanced analytics, and modular automation enhance process control and enable predictive maintenance, but they also raise the bar for data integrity and interoperability across partners. Third, commercial and regulatory expectations are converging on earlier alignment between sponsors and providers, which incentivizes integrated service offerings spanning analytical, process development, and clinical supply. Fourth, capital constraints and the pursuit of faster time-to-revenue are encouraging strategic partnerships, joint ventures, and asset-light models that distribute risk while preserving strategic optionality.

These shifts collectively favor organizations that combine technical depth with flexible capacity, robust digital infrastructure, and the governance mechanisms to manage complex multi-stakeholder projects. In the months ahead, the ability to translate platform competencies into reproducible outcomes will determine which providers capture the most durable client relationships.

Examining how recent tariff policy shifts and trade dynamics are amplifying supply chain risk and compelling strategic realignment across outsourced pharmaceutical development and manufacturing

Policy changes affecting tariffs and trade flows have material implications for global manufacturing and the clinical supply chain, and the cumulative effects of tariff measures enacted or signaled in 2025 have amplified strategic reassessment across the industry. Increased import duties on active pharmaceutical ingredients, single-use components, and specialized equipment raise landed costs for outsourced production and can slightly elongate lead times due to shifted sourcing and customs clearance practices. In response, many sponsors and providers are reevaluating supplier footprints to balance cost, lead-time certainty, and regulatory compliance.

As a consequence, organizations are accelerating diversification strategies that include alternate sourcing, dual-sourcing arrangements, and regional capacity expansion to mitigate concentrated exposure. Nearshoring and onshoring initiatives have gained renewed attention where regulatory regimes and local incentives align to offset tariff-related cost pressures. Furthermore, procurement teams are increasingly incorporating total landed cost analyses, factoring in duties, insurance, transport, and potential regulatory retesting when selecting suppliers.

From an operational perspective, the tariff environment has underscored the importance of inventory strategy and demand forecasting. Sponsors reliant on critical inputs with constrained supplier bases are prioritizing safety-stock policies and strengthening contractual clauses around lead times and quality assurance. Ultimately, the tariff environment has accelerated strategic shifts toward resilient supply chains, localized capabilities, and deeper collaboration between sponsors and outsourced providers to preserve program timelines and product quality.

Comprehensive segmentation insights that map service modalities, product complexities, therapeutic applications, and end-user characteristics to strategic capability requirements and partnership models

A granular segmentation view illuminates where capabilities, regulatory demands, and commercial priorities intersect across service types, product classes, therapeutic applications, and end-user profiles. Service offerings include analytical workstreams, cell culture operations, clinical development support, fill-finish capabilities, formulation expertise, preclinical development, and process development; within clinical development, support spans Phase I through Phase III activities, each with distinct regulatory touchpoints and supply requirements. Product types bifurcate into large molecules and small molecules, where the large molecule category includes biologics and biosimilars, and biologics themselves encompass monoclonal antibodies, recombinant proteins, and vaccines. Small molecules cover generics and new chemical entities, with different speed-to-clinic dynamics and manufacturing footprints.

Applications further define technical requirements: cell therapies, comprising CAR T and stem cell approaches, demand closed systems, specialized cold-chain logistics, and stringent chain-of-custody controls, while gene therapies-divided into non-viral and viral vector platforms-require dedicated containment, vector production expertise, and unique analytical paradigms. Monoclonal antibodies include bispecific, conjugated, and naked variants, each with distinct purification and characterization needs. Recombinant proteins span enzymes, growth factors, and hormones, requiring specific expression systems and downstream processing strategies. Vaccines span inactivated, live attenuated, mRNA, and subunit formats, each bringing unique temperature, stability, and fill-finish challenges.

End users vary in scale and strategic intent: biotechnology companies range from large integrated organizations to small innovators with high experimental throughput; CROs may offer full-service capabilities or niche expertise; pharmaceutical companies are tiered by their global reach and internal capacity; and research institutions include academic centers and government laboratories focused on translational science. These distinctions influence procurement cycles, quality expectations, and partnership models. Taken together, segmentation reveals where investment in specialized capabilities, regulatory engagement, and commercial alignment will deliver the most value and competitive differentiation.

Regional strategic implications for facility investment, regulatory alignment, and partner selection across the Americas, EMEA, and Asia-Pacific ecosystems

Geographic context plays a decisive role in shaping capacity investment, regulatory strategy, and commercial outreach across the contract development and manufacturing ecosystem. The Americas present a mature environment characterized by established regulatory frameworks, a deep talent pool in biologics and advanced therapies, and significant private and public capital flowing into capacity expansion, particularly in regions with strong logistics and clinical ecosystems. This environment favors sponsors and providers that can leverage integrated networks spanning development, clinical trial execution, and commercial supply.

Europe, the Middle East, and Africa encompass a mosaic of regulatory regimes and incentive structures. Western European markets are notable for their high regulatory standards, strong academic-industry collaborations, and a robust presence of specialized service providers. The Middle East and select African markets are increasingly attractive for strategic partnerships and manufacturing hubs when paired with targeted incentives and investment in workforce development, although regulatory harmonization remains an implementation task in many jurisdictions.

Asia-Pacific combines rapid capacity expansion with divergent regulatory timelines and varied labor cost structures. Several economies in the region are investing heavily in state-of-the-art facilities and workforce training to capture a larger share of complex biologics and advanced therapy manufacturing. For sponsors, this regional mix requires nuanced partner selection that balances cost, speed, and regulatory alignment. Across all regions, cross-border regulatory coordination, logistics, and local talent development are key determinants of where sponsors elect to allocate development and manufacturing work.

Key observations on how technical depth, strategic partnerships, and digital-enabled operational excellence are redefining leadership in outsourced pharmaceutical development and manufacturing

Competitive dynamics among service providers are increasingly defined by depth of technical platforms, the ability to integrate across development stages, and the agility to support complex modalities. Leading firms are differentiating through investments in specialized facilities, proprietary analytical platforms, and automation that reduce variability and accelerate release testing. At the same time, a cohort of nimble niche providers is capitalizing on focused expertise-such as viral vector manufacturing, CAR T processing, or advanced fill-finish for mRNA products-by offering flexible, client-centric arrangements that appeal to emerging biotech sponsors.

Strategic partnerships and alliance models remain central to capability expansion. Sponsors and providers are pursuing co-investments, joint ventures, and long-term capacity reservations to secure access to scarce resources and to align incentives across development and commercialization phases. Operational excellence in quality systems, data integrity, and regulatory engagement is a non-negotiable differentiator; providers that demonstrate consistent compliance histories and transparent audit trails are winning multi-year engagements.

Additionally, service organizations that successfully marry digital platforms-enabling real-time analytics, batch tracking, and predictive maintenance-with process expertise are setting new expectations for responsiveness and transparency. Talent strategies are also evolving, with investments in cross-disciplinary teams that blend process science, regulatory affairs, and digital proficiency becoming essential to deliver complex programs reliably and at scale.

Actionable and prioritized recommendations for executives to strengthen operational resilience, regulatory readiness, and strategic partnerships across outsourced development and manufacturing

Industry leaders should adopt a set of pragmatic, prioritized actions to protect program timelines, enhance flexibility, and capture commercial advantage. First, sponsors and providers must accelerate investments in platform technologies and modular facility designs that enable rapid molecule transfer and scalable manufacturing without compromising quality. This includes targeted capital deployment for high-impact capabilities such as viral vector suites, closed-system cell therapy production, and advanced fill-finish lines that support temperature-sensitive formats.

Second, diversify sourcing and contractual arrangements to mitigate geopolitical and tariff-driven disruptions by establishing alternate suppliers, dual-sourcing critical inputs, and pursuing regionally balanced capacity. Third, strengthen regulatory engagement through early and frequent dialogue with authorities and adopt robust data management frameworks that support electronic submissions and traceability across partner networks. Fourth, prioritize talent development and retention strategies that build cross-functional competencies in process science, quality assurance, and digital operations, thereby reducing dependency on scarce external expertise.

Finally, formalize strategic collaborations using clear governance structures and shared KPIs to align incentives across multi-stakeholder projects. By taking these steps, organizations can reduce program risk, improve time-to-patient, and position themselves to capture the benefits of accelerating therapeutic innovation.

A rigorous and transparent multi-method research approach combining executive interviews, technical consultations, and secondary evidence to produce practitioner-focused insights and recommendations

This research synthesizes a multi-method approach designed to ensure robust, reproducible insights that reflect current industry dynamics and practitioner experience. The methodology combines primary qualitative interviews with senior executives across sponsor, provider, and institutional stakeholder groups, supplemented by technical consultations with process scientists, regulatory experts, and supply chain professionals to validate operational impacts. These conversations were structured to elicit practical perspectives on capacity constraints, technology adoption, and partnership models rather than to produce quantitative forecasts.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, industry white papers, and company disclosures to contextualize primary findings and identify emergent patterns in investment and capability development. Data triangulation was employed to reconcile divergent viewpoints and to isolate consistent themes across geographies, service lines, and product modalities. Throughout, particular attention was given to methodological transparency, including documenting assumptions, interview sampling frames, and criteria used to classify service and product types.

Finally, iterative analyst workshops were convened to stress-test conclusions, ensuring that recommendations are actionable and grounded in real-world constraints. The approach emphasizes qualitative rigor and practitioner relevance to support decision-makers seeking to translate insight into operational plans.

A concise conclusion synthesizing how capability investment, regulatory alignment, and resilient partnerships will determine long-term competitiveness in outsourced therapeutics development

The cumulative picture is one of an industry at an inflection point where scientific innovation, operational complexity, and geopolitical dynamics intersect to redefine outsourcing strategy. Sponsors and providers that invest selectively in specialized capabilities, digital infrastructure, and resilient supply networks will be better positioned to de-risk development programs and accelerate patient access. Equally important is the adoption of partnership frameworks that align incentives and enable shared accountability for quality and timeline outcomes.

Operational resilience, regulatory engagement, and talent development emerge as the foundational pillars for success. Organizations that cultivate cross-functional teams, establish robust data governance, and pursue flexible sourcing arrangements can convert external shocks into manageable variances rather than catastrophic delays. As the industry continues to evolve, the ability to translate technical expertise into reproducible, auditable processes will determine which players sustain long-term partnerships and capture a disproportionate share of complex therapy programs.

In closing, the sector's trajectory favors those who combine scientific excellence with disciplined execution and strategic foresight. The decisions companies make today regarding capacity, technology, and collaborative models will shape competitive positioning for years to come.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical CMO & CRO Market, by Product Type

  • 8.1. Large Molecule
    • 8.1.1. Biologics
      • 8.1.1.1. Monoclonal Antibodies
      • 8.1.1.2. Recombinant Proteins
      • 8.1.1.3. Vaccines
    • 8.1.2. Biosimilars
  • 8.2. Small Molecule
    • 8.2.1. Generics
    • 8.2.2. New Chemical Entities

9. Biopharmaceutical CMO & CRO Market, by Service Type

  • 9.1. Analytical
  • 9.2. Cell Culture
  • 9.3. Clinical Development
    • 9.3.1. Phase I
    • 9.3.2. Phase II
    • 9.3.3. Phase III
  • 9.4. Fill-Finish
  • 9.5. Formulation
  • 9.6. Preclinical Development
  • 9.7. Process Development

10. Biopharmaceutical CMO & CRO Market, by Therapeutic Area

  • 10.1. Oncology
  • 10.2. Infectious Diseases
  • 10.3. Cardiovascular
  • 10.4. Central Nervous System
  • 10.5. Immunology And Inflammation
  • 10.6. Respiratory
  • 10.7. Metabolic And Endocrine
  • 10.8. Rare Diseases

11. Biopharmaceutical CMO & CRO Market, by Application

  • 11.1. Cell Therapies
    • 11.1.1. CAR T
    • 11.1.2. Stem Cell
  • 11.2. Gene Therapies
    • 11.2.1. Non Viral
    • 11.2.2. Viral Vector
  • 11.3. Monoclonal Antibodies
    • 11.3.1. Bispecific
    • 11.3.2. Conjugated
    • 11.3.3. Naked
  • 11.4. Recombinant Proteins
    • 11.4.1. Enzymes
    • 11.4.2. Growth Factors
    • 11.4.3. Hormones
  • 11.5. Vaccines
    • 11.5.1. Inactivated
    • 11.5.2. Live Attenuated
    • 11.5.3. mRNA
    • 11.5.4. Subunit

12. Biopharmaceutical CMO & CRO Market, by End User

  • 12.1. Biotechnology Companies
    • 12.1.1. Large Biotech
    • 12.1.2. Small Biotech
  • 12.2. CROs
    • 12.2.1. Full Service
    • 12.2.2. Niche Service
  • 12.3. Pharmaceutical Companies
    • 12.3.1. Tier I
    • 12.3.2. Tier II
    • 12.3.3. Tier III
  • 12.4. Research Institutions
    • 12.4.1. Academia
    • 12.4.2. Government

13. Biopharmaceutical CMO & CRO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceutical CMO & CRO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceutical CMO & CRO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopharmaceutical CMO & CRO Market

17. China Biopharmaceutical CMO & CRO Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AbbVie, Inc.
  • 18.7. arexel International Corporation
  • 18.8. Baxter International Inc.
  • 18.9. Boehringer Ingelheim Biopharmaceuticals GmbH
  • 18.10. Boehringer Ingelheim GmbH
  • 18.11. Catalent, Inc.
  • 18.12. Charles River Laboratories International, Inc.
  • 18.13. Eurofins Scientific Limited
  • 18.14. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 18.15. ICON Plc
  • 18.16. KBI Biopharma, Inc.
  • 18.17. KEMWELL BIOPHARMA PRIVATE LIMITED
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. Lonza Group AG
  • 18.20. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • 18.21. Patheon Inc.
  • 18.22. Rentschler Biopharma SE
  • 18.23. Sterling Pharma Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 20